Clinical Outcomes of First-line Abiraterone Acetate or Enzalutamide for Metastatic Castration-resistant Prostate Cancer After Androgen Deprivation Therapy thorn Docetaxel or ADT Alone for Metastatic Hormone-sensitive Prostate Cancer

Edoardo Francini; Steven Yip; Shubidito Ahmed; Haocheng Li; Luke Ardolino; Carolyn P. Evan; Marina Kaymakcalan; Grace K. Shaw; Philip W. Kantoff; Mary-Ellen Taplin; Nimira S. Alimohamed; Anthony M. Joshua; Daniel Y. C. Heng; Christopher J. Sweeney

doi:10.1016/j.clgc.2017.12.012

Back

Clinical Outcomes of First-line Abiraterone Acetate or Enzalutamide for Metastatic Castration-resistant Prostate Cancer After Androgen Deprivation Therapy thorn Docetaxel or ADT Alone for Metastatic Hormone-sensitive Prostate Cancer

Journal article

Peer reviewed

Clinical Outcomes of First-line Abiraterone Acetate or Enzalutamide for Metastatic Castration-resistant Prostate Cancer After Androgen Deprivation Therapy thorn Docetaxel or ADT Alone for Metastatic Hormone-sensitive Prostate Cancer

Edoardo Francini, Steven Yip, Shubidito Ahmed, Haocheng Li, Luke Ardolino, Carolyn P. Evan, Marina Kaymakcalan, Grace K. Shaw, Philip W. Kantoff, Mary-Ellen Taplin, …

Clinical genitourinary cancer, Vol.16(2), pp.130-134

04/01/2018

DOI: 10.1016/j.clgc.2017.12.012

PMID: 29331381

Files and links (1)

url

https://doi.org/10.1016/j.clgc.2017.12.012View

Published (Version of record) Open Access

Abstract

Although an androgen deprivation therapy plus docetaxel regimen was shown to extend the survival of some patients with metastatic hormone-sensitive prostate cancer compared with androgen deprivation therapy alone, currently, there is no report in the literature investigating the impact of upfront docetaxel on subsequent first-line abiraterone acetate or enzalutamide for metastatic castration-resistant prostate cancer. This study showed that their activity is maintained regardless of previous use of docetaxel for metastatic hormone-sensitive prostate cancer. These findings can aid treatment decision-making. Background: The CHAARTED (ChemoHormonal Therapy Versus Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer) and STAMPEDE (Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy) trials showed that the addition of docetaxel (D) to androgen deprivation therapy (ADT) prolonged longevity of men with metastatic hormone-sensitive prostate cancer (mHSPC). However, the impact of upfront D on subsequent therapies is still unexplored. As abiraterone acetate (AA) and enzalutamide (E) are the most commonly used first-line treatment for metastatic castration-resistant prostate cancer (mCRPC), we aimed to assess whether they maintained their efficacy after ADT+D versus ADT alone. Patients and Methods: A cohort of patients with mCRPC treated between 2014 and 2017 with first-line AA or E for mCRPC was identified from 3 hospitals' institutional review board-approved databases. Patients were classified by use of D for mHSPC. This time frame was chosen as ADT+D became a valid therapeutic option for mHSPC in 2014, and it inherently entailed a short follow-up time on AA/E. The endpoints included overall survival from ADT start, overall survival from AA/E start, and time to AA/E start from ADT start. Differences between groups were assessed using the log-rank test. Results: Of the 102 patients with mCRPC identified, 50 (49%) had previously received ADT alone, while 52 (51%) had ADT+D. No statistically significant difference in any of the evaluated outcomes was observed between the 2 cohorts. Yet, deaths in the ADT+D group were 12 versus 21 in the ADT alone, after a median follow-up of 24.4 and 29.8 months, respectively. Conclusion: In a cohort of ADT/ADT+D-treated patients with mCRPC with short times to first-line AA/E and follow-up, the efficacy of AA/E is similar regardless of previous use of D. (C) 2017 Elsevier Inc. All rights reserved.

Life Sciences & Biomedicine

Oncology

Science & Technology

Urology & Nephrology

Details

Title: Subtitle: Clinical Outcomes of First-line Abiraterone Acetate or Enzalutamide for Metastatic Castration-resistant Prostate Cancer After Androgen Deprivation Therapy thorn Docetaxel or ADT Alone for Metastatic Hormone-sensitive Prostate Cancer
Creators: Edoardo Francini - Harvard University
Steven Yip - Tom Baker Canc Clin, Calgary, AB, Canada
Shubidito Ahmed - Tom Baker Canc Clin, Calgary, AB, Canada
Haocheng Li - University of Calgary
Luke Ardolino - St Vincent's Hospital Sydney
Carolyn P. Evan - Harvard University
Marina Kaymakcalan - Dana-Farber Cancer Institute
Grace K. Shaw - Harvard University
Philip W. Kantoff - Memorial Sloan Kettering Cancer Center
Mary-Ellen Taplin - Harvard Med Sch, Dana Farber Canc Inst, Boston, MA USA
Nimira S. Alimohamed - Tom Baker Canc Clin, Calgary, AB, Canada
Anthony M. Joshua - St Vincent's Hospital Sydney
Daniel Y. C. Heng - Tom Baker Canc Clin, Calgary, AB, Canada
Christopher J. Sweeney - Harvard University
Resource Type: Journal article
Publication Details: Clinical genitourinary cancer, Vol.16(2), pp.130-134
DOI: 10.1016/j.clgc.2017.12.012
PMID: 29331381
ISSN: 1558-7673
eISSN: 1938-0682
Publisher: Cig Media Group, Lp
Number of pages: 5
Grant note: Tarveda Therapeutics Sotio Progenity Sanofi; Sanofi-Aventis Takeda; Takeda Pharmaceutical Company Ltd BMS; Bristol-Myers Squibb Theragen MTG Therapeutics Genentech/Roche; Roche Holding; Genentech Medivation
Language: English
Date published: 04/01/2018
Academic Unit: Internal Medicine
Record Identifier: 9985221144002771

Metrics

1 Record Views

19 Times Cited - Web of Science